STOCK TITAN

Bausch Health Companies Inc. - BHC STOCK NEWS

Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.

With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.

Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.

Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.

Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.

For more information, visit www.bauschhealth.com.

Rhea-AI Summary
Bausch Health CFO resigns, interim replacement identified
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
none
-
Rhea-AI Summary
Bausch Health announces availability of new treatment for ulcerative colitis in Canada
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb launches $1.4 billion offering of senior secured notes and seeks to enter into an incremental term loan facility. The proceeds will fund the pending acquisition of XIIDRA® and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Rhea-AI Summary
Bausch + Lomb discloses financial information regarding the proposed acquisition of XIIDRA® and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
-
Rhea-AI Summary
Bausch Health Companies Inc. announces favorable motion ruling in Xifaxan litigation, raises revenue outlook, and provides updates on balance sheet initiatives and potential Bausch + Lomb distribution. Q2 2023 revenue of $2.17 billion, up 10% reported and 11% organically. CEO cites focus on commercial excellence and growth opportunities. R&D pipeline updates shared. Consolidated operating income increases to $412 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
Rhea-AI Summary
Bausch Health Companies Inc. and Ortho Dermatologics have announced the recipients of their 2023 Aspire Higher Scholarship program. The program has provided a total of $978,000 in scholarships since 2013 and will award six students with up to $10,000 each to pursue their undergraduate or graduate degrees. The recipients were chosen from 216 applications based on their essays and the role of healthcare professionals in treating their dermatologic conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals have announced the winners of the 2023 Salix Gastrointestinal Health Scholars Program. 10 students with gastrointestinal diseases will each receive a $10,000 scholarship. The recipients were selected from over 225 applications and scholarships were awarded in four categories: Undergraduate Scholar Awards, Graduate Scholar Awards, Working Parent's Scholar Award, and Single Parent's Scholar Award.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

The current stock price of Bausch Health Companies (BHC) is $8.48 as of November 15, 2024.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately 3.2B.

What are the primary areas of focus for Bausch Health?

Bausch Health specializes in eye health, gastroenterology, and dermatology.

How many employees does Bausch Health have?

Bausch Health employs approximately 22,000 people worldwide.

In how many countries does Bausch Health operate?

Bausch Health operates in around 100 countries.

What is Bausch Health's largest revenue-generating segment?

The Bausch + Lomb segment generates the highest revenue for Bausch Health.

What recent product development has Bausch Health achieved?

Bausch Health has made significant progress with Amiselimod, a new treatment for ulcerative colitis.

What financial performance did Bausch Health report for Q1 2024?

Bausch Health reported Q1 2024 revenues of $2.15 billion, an 11% increase from the previous year.

How is Bausch Health protecting its intellectual property?

Bausch Health is actively involved in litigation to defend its intellectual property, particularly for the XIFAXAN® franchise.

Where can I find more information about Bausch Health?

More information is available at www.bauschhealth.com.

What recent public drug plan listings has Bausch Health achieved in Canada?

UCERIS® aerosol foam has been listed in the public drug plans of several Canadian provinces, including Ontario, Quebec, and Alberta.

Who is the brand ambassador for the XIFAXAN® awareness campaign?

Award-winning actor Bellamy Young is the brand ambassador for the XIFAXAN® awareness campaign.

Bausch Health Companies Inc.

NYSE:BHC

BHC Rankings

BHC Stock Data

3.17B
367.80M
11.08%
77.48%
3.27%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
QUEBEC